View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsWellbiotec 将来の成長Future 基準チェック /06現在、 Wellbiotecの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Luxury 収益成長14.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • Jan 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Internal Director Choon-Jae Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Mar 18Wellbiotec Co., Ltd., Annual General Meeting, Mar 31, 2025Wellbiotec Co., Ltd., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 17, yeongdong-daero 106-gil, gangnam-gu, seoul South KoreaReported Earnings • Apr 10Full year 2023 earnings released: ₩820 loss per share (vs ₩325 loss in FY 2022)Full year 2023 results: ₩820 loss per share (further deteriorated from ₩325 loss in FY 2022). Revenue: ₩72.1b (down 54% from FY 2022). Net loss: ₩64.9b (loss widened 211% from FY 2022). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.New Risk • Apr 05New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (37% increase in shares outstanding). Market cap is less than US$100m (₩53.2b market cap, or US$39.4m).分析記事 • Mar 22Take Care Before Jumping Onto Wellbiotec Co., Ltd. (KRX:010600) Even Though It's 28% CheaperTo the annoyance of some shareholders, Wellbiotec Co., Ltd. ( KRX:010600 ) shares are down a considerable 28% in the...New Risk • Nov 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩134.6b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 0.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (37% increase in shares outstanding). Market cap is less than US$100m (₩134.6b market cap, or US$99.1m).お知らせ • Jun 14Wellbiotec Co., Ltd. announced that it has received KRW 8.00000001 billion in funding from K-Impact FundOn June 13, 2023, Wellbiotec Co., Ltd. closed the transaction.Reported Earnings • May 18First quarter 2023 earnings released: ₩8.00 loss per share (vs ₩63.00 profit in 1Q 2022)First quarter 2023 results: ₩8.00 loss per share (down from ₩63.00 profit in 1Q 2022). Revenue: ₩26.5b (down 57% from 1Q 2022). Net loss: ₩520.6m (down 114% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 26Full year 2022 earnings released: ₩98.00 loss per share (vs ₩383 loss in FY 2021)Full year 2022 results: ₩98.00 loss per share (improved from ₩383 loss in FY 2021). Revenue: ₩190.9b (up 57% from FY 2021). Net loss: ₩6.28b (loss narrowed 70% from FY 2021). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.お知らせ • Feb 08Wellbiotec Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank, Investment ArmWellbiotec Co., Ltd. announced a private placement of series 32 Unsecured privately placed convertible bonds with bearer interest for the gross proceeds of KRW 10,000,000,000 on February 7, 2023. The transaction will include participation from retuning investor Sangsangin Savings Bank, Investment Arm and Sangsangin Plus Savings Bank Co.,Ltd. for KRW 5,000,000,000 each. The bonds are 100% convertible into 8,841,732 shares at a fixed conversion price of KRW 1,131 per share from February 9, 2024 to January 09, 2026. The bonds bear 3% interest rate and 8% yield to maturity and will mature on February 9, 2026. The transaction has been approved by the board of directors and is expected to close on February 9, 2023. The bonds are restricted to a hold period of one year from the date of issuance.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Internal Director Choon-Jae Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Jun 22Wellbiotec Co., Ltd. announced that it expects to receive KRW 3 billion in funding from KH Feelux Co., Ltd.Wellbiotec Co., Ltd. announced a private placement of 31st series no-guaranteed Private convertible bonds with barer type interest part convertible bonds for gross proceeds of KRW 3,000,000,000 on June 21, 2022. The transaction included participation from new investor KH Feelux Co., Ltd. The bonds are having coupon rate 5% and will mature on June 22, 2025. The bonds will be 100% convertible into 1,951,854 common shares of the company at a fixed conversion price of KRW 1,537 per share from June 22, 2023 to May 25, 2025. The board of directors of the company approved the transaction. The subscription and payment date are June 22, 2022.Reported Earnings • May 18First quarter 2022 earnings released: EPS: ₩63.00 (vs ₩44.00 loss in 1Q 2021)First quarter 2022 results: EPS: ₩63.00 (up from ₩44.00 loss in 1Q 2021). Revenue: ₩62.1b (up 262% from 1Q 2021). Net income: ₩3.68b (up ₩5.76b from 1Q 2021). Profit margin: 5.9% (up from net loss in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 14% per year.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Internal Director Choon-Jae Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 16Wellbiotec Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Wise Pacific Holdings LimitedWellbiotec Co., Ltd. (KOSE:A010600) announced a private placement of round 29th and 30th non-guaranteed private equity convertible bonds with bearer interest for gross proceeds of KRW 10,000,000,000 on April 14, 2021. The transaction will include participation from Rover Holdings Co., Ltd. and returning investor Wise Pacific Holdings Limited for KRW 5,000,000,000 each. The bond is issued at maturity interest rate of 4% and surface interest rate of 0%. The 29th bond will mature on May 14, 2024 and 30th bond will mature on June 14, 2024. The bonds will be 100% convertible into 2,833,662 common shares at a fixed conversion price of KRW 3,529 per share. The 29th bonds will convert from May 14, 2022 to April 14, 2024 and 30th bonds will convert from June 14, 2022 to May 14, 2024. The board of directors of the company approved the transaction. The payment date for 29th bonds is May 14, 2021 and 30th bonds is June 14, 2021.The bonds issued in the transaction will have a hold period of one year from the date of issuance.お知らせ • Mar 11Wellbiotec Co., Ltd., Annual General Meeting, Mar 30, 2021Wellbiotec Co., Ltd., Annual General Meeting, Mar 30, 2021, at 09:00 Korea Standard Time.お知らせ • Feb 27+ 2 more updatesWellbiotec Co., Ltd. announced that it has received KRW 15 billion in funding from Sangsangin Savings Bank, Investment Arm, Sangsangin Plus Savings Bank, Investment ArmOn February 26, 2021, Wellbiotec Co., Ltd. (KOSE:A010600) closed the transaction.Is New 90 Day High Low • Feb 26New 90-day high: ₩2,955The company is up 28% from its price of ₩2,300 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Luxury industry, which is up 20% over the same period.Is New 90 Day High Low • Jan 22New 90-day high: ₩2,780The company is up 29% from its price of ₩2,155 on 23 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Luxury industry, which is up 11% over the same period.Is New 90 Day High Low • Jan 05New 90-day high: ₩2,660The company is up 17% from its price of ₩2,275 on 07 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Luxury industry, which is up 8.0% over the same period.Is New 90 Day High Low • Dec 15New 90-day high: ₩2,550The company is up 3.0% from its price of ₩2,470 on 16 September 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 5.0% over the same period.分析記事 • Dec 11Here's Why Wellbiotec (KRX:010600) Can Afford Some DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is New 90 Day High Low • Oct 26New 90-day low: ₩2,060The company is down 41% from its price of ₩3,480 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 14% over the same period.Is New 90 Day High Low • Oct 08New 90-day low: ₩2,215The company is down 23% from its price of ₩2,875 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 6.0% over the same period.お知らせ • Aug 27Wellbiotec Co., Ltd. (KOSE:A010600) agreed to acquire Kumyoungeng Co., Ltd from Seungho Choi for KRW 35 billion.Wellbiotec Co., Ltd. (KOSE:A010600) agreed to acquire Kumyoungeng Co., Ltd from Seungho Choi for KRW 35 billion on August 25, 2020. Wellbiotec Co., Ltd. will acquire 0.05 million shares of Kumyoungeng Co., Ltd. Wellbiotec Co., Ltd. shall pay KRW 2.5 billion as down payment on the contract date, KRW 17.5 billion on October 7, 2020 and balance of KRW 15 billion on November 6, 2020. For the period ending December 2019, Kumyoungeng Co., Ltd reported total assets of KRW 27.75 billion, total equity of KRW 15.86 billion, sales of KRW 50.29 billion and net income of KRW 3.72 billion. The transaction is expected to complete on November 6, 2020. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Wellbiotec は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSE:A010600 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/202579,765-13,095-2,852-2,441N/A6/30/202582,879-16,60827448N/A3/31/202587,282-17,947-996-573N/A12/31/202483,301-19,062-6,167-6,077N/A9/30/202446,620-68,6522,2422,267N/A6/30/202448,773-65,525-13,541-13,336N/A3/31/202450,873-60,260-12,321-11,846N/A12/31/202359,746-59,082-5,072-4,168N/A9/30/202374,680-22,525-12,703-11,636N/A6/30/202396,222-23,2966031,371N/A3/31/2023122,501-25,086-26,359-25,589N/A12/31/2022158,116-20,8811,4711,980N/A9/30/2022157,959-25,95316,29817,269N/A6/30/2022164,626-23,4228,4299,512N/A3/31/2022153,331-29,09931,29632,227N/A12/31/2021108,377-34,861-227536N/A9/30/2021107,138-24,727-15,984-15,355N/A6/30/202175,149-31,380-7,459-6,817N/A3/31/202159,256-50,769-2,385-1,201N/A12/31/202060,431-50,513-6,981-5,705N/A9/30/202058,699-34,163-6,612-5,695N/A6/30/202057,809-28,582-6,880-5,899N/A3/31/202053,086-7,917-12,613-12,060N/A12/31/201952,333-4,333-13,828-7,727N/A9/30/201974,363-9,321-17,996-11,507N/A6/30/201974,922-11,345N/A-18,471N/A3/31/201974,007-11,436N/A-11,346N/A12/31/201873,932-13,754N/A-9,275N/A9/30/201875,574-15,466N/A-7,270N/A6/30/201871,854-12,032N/A-2,809N/A3/31/201872,043-8,018N/A-5,781N/A12/31/201770,786-8,742N/A-4,018N/A9/30/201773,822-2,944N/A-2,978N/A6/30/201779,188-4,797N/A-1,830N/A3/31/201780,912-4,502N/A-508N/A12/31/201685,292-2,450N/A-2,366N/A9/30/201693,394-2,163N/A75N/A6/30/201698,733-135N/A683N/A3/31/2016105,336766N/A3,234N/A12/31/2015112,488550N/A4,277N/A9/30/2015115,378-5,577N/A2,291N/A6/30/2015116,840-5,579N/A2,333N/A3/31/2015115,684-7,697N/A-874N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A010600の予測収益成長が 貯蓄率 ( 3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A010600の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A010600の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A010600の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A010600の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A010600の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YConsumer-durables 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/01/27 17:53終値2026/01/23 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Wellbiotec Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • Jan 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Internal Director Choon-Jae Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Mar 18Wellbiotec Co., Ltd., Annual General Meeting, Mar 31, 2025Wellbiotec Co., Ltd., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 17, yeongdong-daero 106-gil, gangnam-gu, seoul South Korea
Reported Earnings • Apr 10Full year 2023 earnings released: ₩820 loss per share (vs ₩325 loss in FY 2022)Full year 2023 results: ₩820 loss per share (further deteriorated from ₩325 loss in FY 2022). Revenue: ₩72.1b (down 54% from FY 2022). Net loss: ₩64.9b (loss widened 211% from FY 2022). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
New Risk • Apr 05New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (37% increase in shares outstanding). Market cap is less than US$100m (₩53.2b market cap, or US$39.4m).
分析記事 • Mar 22Take Care Before Jumping Onto Wellbiotec Co., Ltd. (KRX:010600) Even Though It's 28% CheaperTo the annoyance of some shareholders, Wellbiotec Co., Ltd. ( KRX:010600 ) shares are down a considerable 28% in the...
New Risk • Nov 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩134.6b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 0.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (37% increase in shares outstanding). Market cap is less than US$100m (₩134.6b market cap, or US$99.1m).
お知らせ • Jun 14Wellbiotec Co., Ltd. announced that it has received KRW 8.00000001 billion in funding from K-Impact FundOn June 13, 2023, Wellbiotec Co., Ltd. closed the transaction.
Reported Earnings • May 18First quarter 2023 earnings released: ₩8.00 loss per share (vs ₩63.00 profit in 1Q 2022)First quarter 2023 results: ₩8.00 loss per share (down from ₩63.00 profit in 1Q 2022). Revenue: ₩26.5b (down 57% from 1Q 2022). Net loss: ₩520.6m (down 114% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 26Full year 2022 earnings released: ₩98.00 loss per share (vs ₩383 loss in FY 2021)Full year 2022 results: ₩98.00 loss per share (improved from ₩383 loss in FY 2021). Revenue: ₩190.9b (up 57% from FY 2021). Net loss: ₩6.28b (loss narrowed 70% from FY 2021). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
お知らせ • Feb 08Wellbiotec Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank, Investment ArmWellbiotec Co., Ltd. announced a private placement of series 32 Unsecured privately placed convertible bonds with bearer interest for the gross proceeds of KRW 10,000,000,000 on February 7, 2023. The transaction will include participation from retuning investor Sangsangin Savings Bank, Investment Arm and Sangsangin Plus Savings Bank Co.,Ltd. for KRW 5,000,000,000 each. The bonds are 100% convertible into 8,841,732 shares at a fixed conversion price of KRW 1,131 per share from February 9, 2024 to January 09, 2026. The bonds bear 3% interest rate and 8% yield to maturity and will mature on February 9, 2026. The transaction has been approved by the board of directors and is expected to close on February 9, 2023. The bonds are restricted to a hold period of one year from the date of issuance.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Internal Director Choon-Jae Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Jun 22Wellbiotec Co., Ltd. announced that it expects to receive KRW 3 billion in funding from KH Feelux Co., Ltd.Wellbiotec Co., Ltd. announced a private placement of 31st series no-guaranteed Private convertible bonds with barer type interest part convertible bonds for gross proceeds of KRW 3,000,000,000 on June 21, 2022. The transaction included participation from new investor KH Feelux Co., Ltd. The bonds are having coupon rate 5% and will mature on June 22, 2025. The bonds will be 100% convertible into 1,951,854 common shares of the company at a fixed conversion price of KRW 1,537 per share from June 22, 2023 to May 25, 2025. The board of directors of the company approved the transaction. The subscription and payment date are June 22, 2022.
Reported Earnings • May 18First quarter 2022 earnings released: EPS: ₩63.00 (vs ₩44.00 loss in 1Q 2021)First quarter 2022 results: EPS: ₩63.00 (up from ₩44.00 loss in 1Q 2021). Revenue: ₩62.1b (up 262% from 1Q 2021). Net income: ₩3.68b (up ₩5.76b from 1Q 2021). Profit margin: 5.9% (up from net loss in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 14% per year.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Internal Director Choon-Jae Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 16Wellbiotec Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Wise Pacific Holdings LimitedWellbiotec Co., Ltd. (KOSE:A010600) announced a private placement of round 29th and 30th non-guaranteed private equity convertible bonds with bearer interest for gross proceeds of KRW 10,000,000,000 on April 14, 2021. The transaction will include participation from Rover Holdings Co., Ltd. and returning investor Wise Pacific Holdings Limited for KRW 5,000,000,000 each. The bond is issued at maturity interest rate of 4% and surface interest rate of 0%. The 29th bond will mature on May 14, 2024 and 30th bond will mature on June 14, 2024. The bonds will be 100% convertible into 2,833,662 common shares at a fixed conversion price of KRW 3,529 per share. The 29th bonds will convert from May 14, 2022 to April 14, 2024 and 30th bonds will convert from June 14, 2022 to May 14, 2024. The board of directors of the company approved the transaction. The payment date for 29th bonds is May 14, 2021 and 30th bonds is June 14, 2021.The bonds issued in the transaction will have a hold period of one year from the date of issuance.
お知らせ • Mar 11Wellbiotec Co., Ltd., Annual General Meeting, Mar 30, 2021Wellbiotec Co., Ltd., Annual General Meeting, Mar 30, 2021, at 09:00 Korea Standard Time.
お知らせ • Feb 27+ 2 more updatesWellbiotec Co., Ltd. announced that it has received KRW 15 billion in funding from Sangsangin Savings Bank, Investment Arm, Sangsangin Plus Savings Bank, Investment ArmOn February 26, 2021, Wellbiotec Co., Ltd. (KOSE:A010600) closed the transaction.
Is New 90 Day High Low • Feb 26New 90-day high: ₩2,955The company is up 28% from its price of ₩2,300 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Luxury industry, which is up 20% over the same period.
Is New 90 Day High Low • Jan 22New 90-day high: ₩2,780The company is up 29% from its price of ₩2,155 on 23 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Luxury industry, which is up 11% over the same period.
Is New 90 Day High Low • Jan 05New 90-day high: ₩2,660The company is up 17% from its price of ₩2,275 on 07 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Luxury industry, which is up 8.0% over the same period.
Is New 90 Day High Low • Dec 15New 90-day high: ₩2,550The company is up 3.0% from its price of ₩2,470 on 16 September 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 5.0% over the same period.
分析記事 • Dec 11Here's Why Wellbiotec (KRX:010600) Can Afford Some DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is New 90 Day High Low • Oct 26New 90-day low: ₩2,060The company is down 41% from its price of ₩3,480 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 14% over the same period.
Is New 90 Day High Low • Oct 08New 90-day low: ₩2,215The company is down 23% from its price of ₩2,875 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 6.0% over the same period.
お知らせ • Aug 27Wellbiotec Co., Ltd. (KOSE:A010600) agreed to acquire Kumyoungeng Co., Ltd from Seungho Choi for KRW 35 billion.Wellbiotec Co., Ltd. (KOSE:A010600) agreed to acquire Kumyoungeng Co., Ltd from Seungho Choi for KRW 35 billion on August 25, 2020. Wellbiotec Co., Ltd. will acquire 0.05 million shares of Kumyoungeng Co., Ltd. Wellbiotec Co., Ltd. shall pay KRW 2.5 billion as down payment on the contract date, KRW 17.5 billion on October 7, 2020 and balance of KRW 15 billion on November 6, 2020. For the period ending December 2019, Kumyoungeng Co., Ltd reported total assets of KRW 27.75 billion, total equity of KRW 15.86 billion, sales of KRW 50.29 billion and net income of KRW 3.72 billion. The transaction is expected to complete on November 6, 2020.